The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder ...

“The analyses from this study add to the body of evidence that show Factor D inhibition can correct dysregulation of the alternative pathway and ... for multiple complement-mediated diseases.

Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) ...

PASADENA, Calif., April 24, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177 ...

Both result from a problem with a specific part of the immune system called the alternative complement pathway. Both types of C3 glomerulopathy can cause significant kidney disease and have a ...

Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this ...

Results from the Phase I and II trials of Ruxoprubart in PNH patients have demonstrated its potential as a highly selective blocker of the alternative pathway (AP). Unlike other complement blockers, ...